Estimation of the Absolute Bioavailability of Rivastigmine in Patients with Mild to Moderate Dementia of the Alzheimer’s Type

Author： Hossain M.  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.41, Iss.3, 2002-01, pp. : 225-234

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rivastigmine Transdermal Patch Skin Tolerability: Results of a 1-Year Clinical Trial in Patients with Mild-to-Moderate Alzheimer's Disease

By Cummings Jeffrey L.  

Clinical Drug Investigation, Vol. 30, Iss. 1, 2010-01 ,pp. : 41-49

Adis International

Access to resources Recommend Favorite

Rivastigmine Transdermal Patch: In the Treatment of Dementia of the Alzheimer's Type

By Yang Lily P.H.   Keating Gillian M.  

CNS Drugs, Vol. 21, Iss. 11, 2007-01 ,pp. : 957-965

Adis International

Access to resources Recommend Favorite

Spotlight on Rivastigmine Transdermal Patch†: In Dementia of the Alzheimer's Type

By Dhillon Sohita  

Drugs & Aging, Vol. 28, Iss. 11, 2011-11 ,pp. : 927-930

Adis International

Access to resources Recommend Favorite

Changes in brain 11C–nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET

By Kadir Ahmadul   Darreh-Shori Taher   Almkvist Ove   Wall Anders   Långström Bengt   Nordberg Agneta  

Psychopharmacology, Vol. 191, Iss. 4, 2007-05 ,pp. : 1005-1014

Springer Publishing Company

Access to resources Recommend Favorite

Donepezil is better tolerated than rivastigmine in mild-to-moderate Alzheimer's disease

By  

Inpharma, Vol. 1, Iss. 1258, 2000-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite